Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK.
Cohen AT, Benson G, Bradbury CA, Choudhuri S, Hutchinson Jones N, Maraveyas A, Venugopal B, Young AM, Chapman C, McIntyre S, Burney D, Pollock KG, Morgan AR, Gabb PD, Alikhan R. Cohen AT, et al. Among authors: maraveyas a. Curr Med Res Opin. 2023 Mar;39(3):483-495. doi: 10.1080/03007995.2023.2167441. Epub 2023 Jan 23. Curr Med Res Opin. 2023. PMID: 36629478 Free article. Review.
Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.
Hutchinson A, Rees S, Young A, Maraveyas A, Date K, Johnson MJ. Hutchinson A, et al. Among authors: maraveyas a. Palliat Med. 2019 May;33(5):510-517. doi: 10.1177/0269216318815377. Epub 2018 Nov 29. Palliat Med. 2019. PMID: 30488789 Free PMC article. Clinical Trial.
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
Noble SI, Nelson A, Fitzmaurice D, Bekkers MJ, Baillie J, Sivell S, Canham J, Smith JD, Casbard A, Cohen A, Cohen D, Evans J, Fletcher K, Johnson M, Maraveyas A, Prout H, Hood K. Noble SI, et al. Among authors: maraveyas a. Health Technol Assess. 2015 Oct;19(83):vii-xxiii, 1-93. doi: 10.3310/hta19830. Health Technol Assess. 2015. PMID: 26490434 Free PMC article. Clinical Trial.
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).
Marshall A, Levine M, Hill C, Hale D, Thirlwall J, Wilkie V, French K, Kakkar A, Lokare A, Maraveyas A, Chapman O, Arif A, Petrou S, Maredza M, Hobbs R, Dunn JA, Young AM. Marshall A, et al. Among authors: maraveyas a. J Thromb Haemost. 2020 Apr;18(4):905-915. doi: 10.1111/jth.14752. Epub 2020 Feb 26. J Thromb Haemost. 2020. PMID: 31995662 Free article. Clinical Trial.
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis.
Schünemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, Noble S, Macbeth F, Griffiths G, Garcia D, Lyman GH, Di Nisio M, Iorio A, Mbuagbaw L, Neumann I, van Es N, Brouwers M, Guyatt G, Streiff MB, Marcucci M, Baldeh T, Florez ID, Alma OG, Solh Z, Bossuyt PM, Kahale LA, Ageno W, Bozas G, Büller HR, Lebeau B, Lecumberri R, Loprinzi C, McBane R, Sideras K, Maraveyas A, Pelzer U, Perry J, Klerk C, Agnelli G, Akl EA. Schünemann HJ, et al. Among authors: maraveyas a. Lancet Haematol. 2020 Oct;7(10):e746-e755. doi: 10.1016/S2352-3026(20)30293-3. Lancet Haematol. 2020. PMID: 32976752
164 results